Propranolol ( DrugBank: Propranolol )


5 diseases
IDDisease name (Link within this page)Number of trials
6Parkinson disease1
158Tuberous sclerosis1
167Marfan syndrome1
227Osler disease1
278Huge lymphatic malformation with cervicofacial lesion1

6. Parkinson disease


Clinical trials : 2,307Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

158. Tuberous sclerosis


Clinical trials : 112Drugs : 71 - (DrugBank : 19) / Drug target genes : 35 - Drug target pathways : 118 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

167. Marfan syndrome


Clinical trials : 21Drugs : 40 - (DrugBank : 11) / Drug target genes : 10 - Drug target pathways : 50 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

227. Osler disease


Clinical trials : 56Drugs : 72 - (DrugBank : 21) / Drug target genes : 23 - Drug target pathways : 136 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

278. Huge lymphatic malformation with cervicofacial lesion


Clinical trials : 19Drugs : 22 - (DrugBank : 7) / Drug target genes : 5 - Drug target pathways : 63 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries